JP2011526244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526244A5 JP2011526244A5 JP2011501003A JP2011501003A JP2011526244A5 JP 2011526244 A5 JP2011526244 A5 JP 2011526244A5 JP 2011501003 A JP2011501003 A JP 2011501003A JP 2011501003 A JP2011501003 A JP 2011501003A JP 2011526244 A5 JP2011526244 A5 JP 2011526244A5
- Authority
- JP
- Japan
- Prior art keywords
- mif
- disease
- cancer
- domain
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 claims 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims 31
- 239000000178 monomer Substances 0.000 claims 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 239000013638 trimer Substances 0.000 claims 12
- 229940044551 receptor antagonist Drugs 0.000 claims 9
- 239000002464 receptor antagonist Substances 0.000 claims 9
- 208000002223 abdominal aortic aneurysm Diseases 0.000 claims 8
- 208000007474 aortic aneurysm Diseases 0.000 claims 8
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 6
- 108090000288 Glycoproteins Proteins 0.000 claims 6
- 102000003886 Glycoproteins Human genes 0.000 claims 6
- 206010028851 Necrosis Diseases 0.000 claims 6
- 206010009887 colitis Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 239000003112 inhibitor Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 claims 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 4
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 4
- 101100001347 Mus musculus Akt1s1 gene Proteins 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010035664 Pneumonia Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 206010040070 Septic Shock Diseases 0.000 claims 4
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 208000007502 anemia Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 206010006451 bronchitis Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 230000003278 mimic effect Effects 0.000 claims 4
- 208000031225 myocardial ischemia Diseases 0.000 claims 4
- 230000017074 necrotic cell death Effects 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims 3
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims 3
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims 3
- 206010018691 Granuloma Diseases 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims 3
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 3
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 3
- 201000009906 Meningitis Diseases 0.000 claims 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 229930013930 alkaloid Natural products 0.000 claims 3
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 3
- 229940100198 alkylating agent Drugs 0.000 claims 3
- 239000002168 alkylating agent Substances 0.000 claims 3
- 230000000781 anti-lymphocytic effect Effects 0.000 claims 3
- 230000000340 anti-metabolite Effects 0.000 claims 3
- 229940100197 antimetabolite Drugs 0.000 claims 3
- 239000002256 antimetabolite Substances 0.000 claims 3
- 239000003435 antirheumatic agent Substances 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 3
- 230000003115 biocidal effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000000139 costimulatory effect Effects 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 230000000779 depleting effect Effects 0.000 claims 3
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 3
- 229940125753 fibrate Drugs 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 3
- 230000036039 immunity Effects 0.000 claims 3
- 239000002955 immunomodulating agent Substances 0.000 claims 3
- 229940121354 immunomodulator Drugs 0.000 claims 3
- 230000002584 immunomodulator Effects 0.000 claims 3
- 239000003607 modifier Substances 0.000 claims 3
- 229960003512 nicotinic acid Drugs 0.000 claims 3
- 235000001968 nicotinic acid Nutrition 0.000 claims 3
- 239000011664 nicotinic acid Substances 0.000 claims 3
- 239000000816 peptidomimetic Substances 0.000 claims 3
- 239000003358 phospholipase A2 inhibitor Substances 0.000 claims 3
- 150000003505 terpenes Chemical class 0.000 claims 3
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 3
- 230000035897 transcription Effects 0.000 claims 3
- 238000013518 transcription Methods 0.000 claims 3
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010001935 American trypanosomiasis Diseases 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 208000027496 Behcet disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000024699 Chagas disease Diseases 0.000 claims 2
- 208000015943 Coeliac disease Diseases 0.000 claims 2
- 206010009895 Colitis ischaemic Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010010741 Conjunctivitis Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 206010058838 Enterocolitis infectious Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 2
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 2
- 201000005569 Gout Diseases 0.000 claims 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 208000001204 Hashimoto Disease Diseases 0.000 claims 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 2
- 208000007514 Herpes zoster Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 208000004852 Lung Injury Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- 208000009433 Moyamoya Disease Diseases 0.000 claims 2
- 208000009525 Myocarditis Diseases 0.000 claims 2
- 208000000592 Nasal Polyps Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000035539 Ovarian infection Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 201000011152 Pemphigus Diseases 0.000 claims 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010038910 Retinitis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims 2
- 241000223109 Trypanosoma cruzi Species 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 208000010668 atopic eczema Diseases 0.000 claims 2
- 230000001363 autoimmune Effects 0.000 claims 2
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000003146 cystitis Diseases 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000007565 gingivitis Diseases 0.000 claims 2
- 206010020718 hyperplasia Diseases 0.000 claims 2
- 208000027138 indeterminate colitis Diseases 0.000 claims 2
- 208000027139 infectious colitis Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 201000008222 ischemic colitis Diseases 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 231100000515 lung injury Toxicity 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 208000016366 nasal cavity polyp Diseases 0.000 claims 2
- 201000008383 nephritis Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 230000003239 periodontal effect Effects 0.000 claims 2
- 208000005987 polymyositis Diseases 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000000649 small cell carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 208000037824 growth disorder Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 230000008477 smooth muscle tissue growth Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3838108P | 2008-03-20 | 2008-03-20 | |
| US61/038,381 | 2008-03-20 | ||
| US3937108P | 2008-03-25 | 2008-03-25 | |
| US61/039,371 | 2008-03-25 | ||
| US4580708P | 2008-04-17 | 2008-04-17 | |
| US61/045,807 | 2008-04-17 | ||
| US12109508P | 2008-12-09 | 2008-12-09 | |
| US61/121,095 | 2008-12-09 | ||
| PCT/US2009/037887 WO2009117710A2 (en) | 2008-03-20 | 2009-03-20 | Methods of treating inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011526244A JP2011526244A (ja) | 2011-10-06 |
| JP2011526244A5 true JP2011526244A5 (https=) | 2011-11-24 |
Family
ID=41091567
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501000A Pending JP2011515416A (ja) | 2008-03-20 | 2009-03-20 | 抗ｍｉｆ抗体を用いる処置方法 |
| JP2011501003A Pending JP2011526244A (ja) | 2008-03-20 | 2009-03-20 | 炎症の処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501000A Pending JP2011515416A (ja) | 2008-03-20 | 2009-03-20 | 抗ｍｉｆ抗体を用いる処置方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110262386A1 (https=) |
| EP (2) | EP2252318A4 (https=) |
| JP (2) | JP2011515416A (https=) |
| KR (1) | KR20110014141A (https=) |
| CN (2) | CN102046199A (https=) |
| AU (2) | AU2009225385A1 (https=) |
| BR (1) | BRPI0910259A2 (https=) |
| CA (2) | CA2717071A1 (https=) |
| CO (1) | CO6300848A2 (https=) |
| EA (1) | EA201001529A1 (https=) |
| IL (1) | IL207752A0 (https=) |
| MX (1) | MX2010010198A (https=) |
| NZ (1) | NZ588033A (https=) |
| WO (2) | WO2009117706A2 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ588033A (en) * | 2008-03-20 | 2012-11-30 | Carolus Therapeutics Inc | Methods of treating a mif-mediated disorder |
| US20110070184A1 (en) * | 2008-03-24 | 2011-03-24 | Carolus Therpeutics, Inc. | Methods and compositions for treating atherosclerosis and related condidtions |
| WO2010056910A2 (en) * | 2008-11-12 | 2010-05-20 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
| CN102725311A (zh) * | 2009-09-23 | 2012-10-10 | 卡罗勒斯治疗公司 | 治疗发炎的方法 |
| EP2308485A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Sulfonamides for the prevention of diabetes |
| EP2308484A1 (en) | 2009-10-06 | 2011-04-13 | Dompé S.p.a. | Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets |
| WO2012125680A1 (en) | 2011-03-16 | 2012-09-20 | Novartis Ag | Methods of treating vasculitis using an il-17 binding molecule |
| WO2012142498A2 (en) * | 2011-04-13 | 2012-10-18 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
| TWI407964B (zh) * | 2011-05-10 | 2013-09-11 | Univ Fu Jen Catholic | 干擾性核糖核酸用於治療或減緩疼痛之用途 |
| EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| US10596233B2 (en) | 2011-06-30 | 2020-03-24 | Dignity Health | Use of pertussis toxin as a therapeutic agent |
| WO2013003786A1 (en) * | 2011-06-30 | 2013-01-03 | Dignity Health | Use of pertussis toxin as a therapeutic agent |
| WO2013010955A1 (en) | 2011-07-15 | 2013-01-24 | Morphosys Ag | Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt) |
| CN102357249A (zh) * | 2011-10-26 | 2012-02-22 | 广州赫尔氏药物开发有限公司 | 能够抑制耐药性结核杆菌的药物 |
| AU2013255050B2 (en) | 2012-05-01 | 2016-07-28 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US10561676B2 (en) * | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| EP3052526A4 (en) | 2013-10-03 | 2017-04-19 | Oregon Health & Science University | Recombinant polypeptides comprising mhc class ii 1 domains |
| ES2924394T3 (es) * | 2015-01-09 | 2022-10-06 | Adalta Ltd | Moléculas de unión a CXCR4 |
| TW201718851A (zh) * | 2015-09-18 | 2017-06-01 | 通用醫院公司 | 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途 |
| CN109069426B (zh) * | 2015-12-14 | 2021-10-29 | X4 制药有限公司 | 治疗癌症的方法 |
| CA3008279A1 (en) | 2015-12-14 | 2017-06-22 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN113893252A (zh) | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| KR102645432B1 (ko) * | 2016-03-28 | 2024-03-11 | (주)아모레퍼시픽 | 피부 세포 분화 촉진용 조성물 및 피부 세포 분화 촉진 물질의 스크리닝 방법 |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| EP3445402A4 (en) * | 2016-04-21 | 2019-12-11 | The Board Of Regents Of The University Of Texas System | METHOD AND COMPOSITIONS FOR DETECTING ANEURYSMS |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| US11291641B2 (en) * | 2016-10-03 | 2022-04-05 | The Children's Medical Center Corporation | Prevention and treatment of diabetic nephropathy |
| CN108355133A (zh) * | 2017-01-26 | 2018-08-03 | 中国医学科学院阜外医院 | 靶向cxcr7的药物组合物和方法 |
| US11767564B2 (en) * | 2017-10-27 | 2023-09-26 | Board Of Regents, The University Of Texas System | Use of SDHA as a prognostic marker and therapeutic target in uveal melanoma |
| CN107964045B (zh) * | 2017-12-18 | 2021-04-23 | 南京医科大学 | 一种人鼠嵌合抗CXCR2全分子IgG及其应用 |
| BR112020020930A2 (pt) | 2018-04-11 | 2021-03-02 | Ohio State Innovation Foundation | composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit |
| US11679146B2 (en) | 2018-06-05 | 2023-06-20 | Anji Pharmaceuticals Inc. | Compositions and methods for treating pancreatitis |
| EP3802595A1 (en) * | 2018-06-07 | 2021-04-14 | OncoOne Research & Development GmbH | Anti-oxmif/anti-cd3 antibody for cancer treatment |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2020139620A1 (en) * | 2018-12-26 | 2020-07-02 | Colgate-Palmolive Company | Biomarkers of neutrophil deregulation as diagnostic for gingivitis |
| CN110133306B (zh) * | 2019-05-09 | 2023-04-07 | 北京勤邦生物技术有限公司 | 检测西马特罗的酶联免疫试剂盒及其应用 |
| CA3171250A1 (en) | 2020-03-10 | 2021-09-16 | E. Lynne KELLEY | Methods for treating neutropenia |
| JP2023517616A (ja) * | 2020-03-11 | 2023-04-26 | バイオラインアールエックス・リミテッド | 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤 |
| WO2021219495A1 (en) * | 2020-04-28 | 2021-11-04 | Dalcor Pharma Uk Ltd., Leatherhead, Zug Branch | Methods for treating or preventing a viral infection or inhibiting viral replication |
| WO2022087719A1 (en) * | 2020-10-28 | 2022-05-05 | University Health Network | Methods of treating spondyloarthritis or symptoms thereof |
| CN117098848A (zh) * | 2021-03-22 | 2023-11-21 | 科列普斯生物医药科技有限公司 | 新型耻垢分枝杆菌重组菌株及其应用 |
| CA3214688A1 (en) | 2021-04-08 | 2022-10-13 | Andrzej KROLEWSKI | Methods of diagnosing and predicting renal decline |
| KR102561554B1 (ko) * | 2021-04-14 | 2023-07-28 | 부산대학교 산학협력단 | 치주질환 진단용 바이오마커 조성물, 치주질환 치료 효용성 평가용 바이오마커 조성물 및 이를 이용한 진단키트 |
| WO2023150294A2 (en) * | 2022-02-04 | 2023-08-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of detecting and treating cerebral aneurysms |
| WO2025171411A1 (en) * | 2024-02-09 | 2025-08-14 | Herophilus, Inc. | Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions |
| CN121714692A (zh) * | 2026-02-26 | 2026-03-24 | 华中科技大学同济医学院附属协和医院 | Cxcl14抑制剂在制备用于预防或治疗患者腹主动脉瘤的药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4708510B2 (ja) * | 1993-05-17 | 2011-06-22 | サイトカイン ファーマサイエンシズ，インコーポレーテッド | サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制 |
| US6645493B1 (en) * | 1993-05-17 | 2003-11-11 | The Picower Institute For Medical Research | Composition containing anti-MIF antibody |
| US7312318B2 (en) * | 2002-03-01 | 2007-12-25 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| US20070072861A1 (en) * | 2000-03-27 | 2007-03-29 | Barbara Roniker | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
| EP1465660A4 (en) * | 2001-01-12 | 2005-09-21 | Cytokine Pharmasciences Inc | METHOD AND COMPOSITIONS FOR MODULATING THE REGULATION OF THE CYTOTOXIC LYMPHOCYTE RESPONSE BY MACROPHAGE MIGRATION HEMM FACTOR |
| JP2003226653A (ja) * | 2001-11-30 | 2003-08-12 | Jun Nishihira | 多発性硬化症治療剤 |
| WO2003047622A1 (fr) * | 2001-11-30 | 2003-06-12 | Jun Nishihira | Remedes pour la sclerose en plaques |
| US6656168B2 (en) * | 2001-12-18 | 2003-12-02 | Kimberly-Clark Worldwide, Inc. | Feminine care product with discrete areas of a skin wellness additive |
| WO2003072753A2 (en) * | 2002-02-27 | 2003-09-04 | Emory University | Multimeric binding complexes |
| EP1569692B1 (en) * | 2002-11-25 | 2010-11-10 | Jallal Messadek | Betaine and salicylic acid compositions |
| TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| US20050202010A1 (en) * | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| US7897349B2 (en) * | 2003-12-30 | 2011-03-01 | The United States Of America As Represented By The Department Of Veterans Affairs | Macrophage migration inhibitory factor (MIF) as marker for urological inflammatory disease |
| WO2006105666A1 (en) * | 2005-04-06 | 2006-10-12 | Queen's University At Kingston | Administration of macrophage targeted formulations of compounds which modulate cholesterol-metabolizing enzymes for treatment of atherosclerosis |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JPWO2007138961A1 (ja) * | 2006-05-29 | 2009-10-08 | レドックス・バイオサイエンス株式会社 | マクロファージ遊走阻止因子阻害剤 |
| NZ588033A (en) * | 2008-03-20 | 2012-11-30 | Carolus Therapeutics Inc | Methods of treating a mif-mediated disorder |
| US20110070184A1 (en) * | 2008-03-24 | 2011-03-24 | Carolus Therpeutics, Inc. | Methods and compositions for treating atherosclerosis and related condidtions |
| WO2010056910A2 (en) * | 2008-11-12 | 2010-05-20 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
| WO2010065491A2 (en) * | 2008-12-01 | 2010-06-10 | Carolus Therapeutics, Inc. | Methods of treating inflammatory disorders |
-
2009
- 2009-03-20 NZ NZ588033A patent/NZ588033A/xx not_active IP Right Cessation
- 2009-03-20 BR BRPI0910259A patent/BRPI0910259A2/pt not_active IP Right Cessation
- 2009-03-20 EA EA201001529A patent/EA201001529A1/ru unknown
- 2009-03-20 EP EP09721240A patent/EP2252318A4/en not_active Withdrawn
- 2009-03-20 US US12/918,964 patent/US20110262386A1/en not_active Abandoned
- 2009-03-20 AU AU2009225385A patent/AU2009225385A1/en not_active Abandoned
- 2009-03-20 KR KR1020107023480A patent/KR20110014141A/ko not_active Withdrawn
- 2009-03-20 CA CA2717071A patent/CA2717071A1/en not_active Abandoned
- 2009-03-20 US US12/918,968 patent/US20110044988A1/en not_active Abandoned
- 2009-03-20 WO PCT/US2009/037883 patent/WO2009117706A2/en not_active Ceased
- 2009-03-20 CN CN200980109905XA patent/CN102046199A/zh active Pending
- 2009-03-20 AU AU2009225389A patent/AU2009225389A1/en not_active Abandoned
- 2009-03-20 JP JP2011501000A patent/JP2011515416A/ja active Pending
- 2009-03-20 MX MX2010010198A patent/MX2010010198A/es active IP Right Grant
- 2009-03-20 JP JP2011501003A patent/JP2011526244A/ja active Pending
- 2009-03-20 CA CA2717365A patent/CA2717365A1/en not_active Abandoned
- 2009-03-20 CN CN2009801093284A patent/CN102088993A/zh active Pending
- 2009-03-20 WO PCT/US2009/037887 patent/WO2009117710A2/en not_active Ceased
- 2009-03-20 EP EP09722541A patent/EP2254597A4/en not_active Withdrawn
-
2010
- 2010-08-23 IL IL207752A patent/IL207752A0/en unknown
- 2010-09-20 CO CO10116141A patent/CO6300848A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526244A5 (https=) | ||
| JP2009530283A5 (https=) | ||
| RU2013144579A (ru) | Ингибиторы киназы mst1 и способы их применения | |
| IL300209A (en) | Dosage preparations containing Bruton's tyrosine kinase inhibitor | |
| JP2019514876A5 (https=) | ||
| CA2769553A1 (en) | Novel pyrimidine and triazine hepcidin antagonists | |
| JP2019514882A5 (https=) | ||
| CY1112805T1 (el) | Παραγωγα πυραζολο (3,4-b) πυριδινης ως αναστολεις της φωσφοδιεστερασης | |
| IL271230B1 (en) | Compounds interacting with the RAS superfamily for the treatment of cancer, inflammation, RAS pathology and fibrotic diseases | |
| JP2018524403A5 (https=) | ||
| JP2018538281A5 (https=) | ||
| JP2017501234A5 (https=) | ||
| JP2012531433A5 (https=) | ||
| JP2019514883A5 (https=) | ||
| JP2011530535A5 (https=) | ||
| CN108601952B (zh) | 雷公藤内酯的葡萄糖缀合物、类似物及其用途 | |
| WO2020083975A1 (en) | Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors | |
| TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| JP2016517273A5 (https=) | ||
| JP2010539237A5 (https=) | ||
| JP2017531002A5 (https=) | ||
| JP2010529986A5 (https=) | ||
| MX2009009234A (es) | Uso nuevo de inhibidores de ciclasa de glutaminilo. | |
| JP2017532360A5 (https=) | ||
| MX2010000334A (es) | Piperazinas sustituidas como antagonistas de cannabinoides 1. |